Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X, ENGOT-ov65/KEYNOTE-B96 investigators

Open source

DOI: 10.1016/s0140-6736(26)00602-1
Published: 2026 Apr 18
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00602-1,
  title = {Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.},
  author = {Colombo N and Zsiros E and Parma G and Rulli E and Sebastianelli A and Bidzinski M and Gallardo C and Matanes E and Hasegawa K and Kose F and Magallanes-Maciel M and Herbertson RA and Ananda S and Kroep JR and de Melo AC and Debruyne PR and Kim JW and Sehouli J and Pierre ME and Hietanen S and Zamagni C and Lu X and Monk BJ and Coleman RL and Peng X and Yamada K and Bogusz AM and De La Motte Rouge T and Wu X and ENGOT-ov65/KEYNOTE-B96 investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00602-1},
  url = {https://doi.org/10.1016/s0140-6736(26)00602-1}
}

RIS

TY  - JOUR
TI  - Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
AU  - Colombo N
AU  - Zsiros E
AU  - Parma G
AU  - Rulli E
AU  - Sebastianelli A
AU  - Bidzinski M
AU  - Gallardo C
AU  - Matanes E
AU  - Hasegawa K
AU  - Kose F
AU  - Magallanes-Maciel M
AU  - Herbertson RA
AU  - Ananda S
AU  - Kroep JR
AU  - de Melo AC
AU  - Debruyne PR
AU  - Kim JW
AU  - Sehouli J
AU  - Pierre ME
AU  - Hietanen S
AU  - Zamagni C
AU  - Lu X
AU  - Monk BJ
AU  - Coleman RL
AU  - Peng X
AU  - Yamada K
AU  - Bogusz AM
AU  - De La Motte Rouge T
AU  - Wu X
AU  - ENGOT-ov65/KEYNOTE-B96 investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00602-1
UR  - https://doi.org/10.1016/s0140-6736(26)00602-1
ER  -

APA

N, C., E, Z., G, P., E, R., A, S., M, B., C, G., E, M., K, H., F, K., M, M., RA, H., S, A., JR, K., AC, D. M., PR, D., JW, K., J, S., ME, P., S, H., C, Z., X, L., BJ, M., RL, C., X, P., K, Y., AM, B., T, D. L. M. R., X, W., & investigators, E. (2026). Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00602-1

Source records

pubmed · retrieved 2026-09-26T07:41:28.352Z